Virtual Library
Start Your Search
Lama Sakr
Author of
-
+
MA09 - Lung Cancer Surgical and Molecular Pathology (ID 908)
- Event: WCLC 2018
- Type: Mini Oral Abstract Session
- Track: Pathology
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 15:15 - 16:45, Room 202 BD
-
+
MA09.09 - EBUS-TBNA in Assessing PD-L1 Expression in NSCLC (ID 13471)
16:15 - 16:20 | Author(s): Lama Sakr
- Abstract
- Presentation
Background
a9ded1e5ce5d75814730bb4caaf49419 Method
Pembrolizumab is the only immunotherapy approved as a first line agent for metastatic NSCLC in patients with high programmed death‐ligand 1 (PD‐L1) expression. The standard samples for PD-L1 testing are considered surgical or core biopsies. In this study, our primary objective is to identify the adequacy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS TBNA) tumor samples in detecting PD-L1 expression.
Between July 2016 and April 2017 a total of 1352 consecutive cases of non-small cell lung cancer (NSCLC) were identified. 29 specimens were deemed inadequate (less than 100 viable tumor cells) and were excluded. 1323 specimens analyzed included surgical samples (N=238), small biopsy (N=744) and cytology cell blocks (N=341). Cytology cell blocks were from EBUS-TBNA (N=190), fine needle aspiration (FNA) (N=61) and pleural/pericardial fluid (N=90). PD-L1 expression was examined by staining with Dako PD-L1 IHC 22C3 pharmDx kit. A Tumor Proportion Score (TPS) was categorized as <1%, 1-49% and ≥ 50% tumor cells.
4c3880bb027f159e801041b1021e88e8 Result
Most of the 1323 specimens (84%) were non-squamous carcinomas. Overall yield for TPS > 50% was 36%. Rate of PD-L1 positivity was no different in non-squamous (37%) compared to squamous (32%). Diagnostic yield of PD-L1 for different sample types varied substantially (Table 1). The EBUS-TBNA samples had the highest yield for TPS ≥ 50% (p=0.025).
8eea62084ca7e541d918e823422bd82e ConclusionTPS Surgical resection Small biopsy EBUS-TBNA FNA Fluid cytology Total Adequacy 100% 99% 98% 96% 92% 98% ≥ 50% 69 (29) 269 (36) 84 (44) 21 (34) 38 (42) 481 1-49% 87 (37) 274 (37) 57 (30) 22 (36) 22 (24) 462 <1% 82 (35) 201 (27) 49 (26) 18 (30) 30 (33) 380 Total 238 744 190 61 90 1323
Our results show that cytology cell blocks could be considered as a valuable resource for PD-L1 testing in advanced NSCLC. Future studies are warranted to explore clinical correlation of PD-L1 on EBUS-TBNA samples and immunotherapy outcome.
6f8b794f3246b0c1e1780bb4d4d5dc53Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.